Tests an active ankle brace on walking speed in people with weak ankle muscles
Tests an active ankle brace against a carbon brace in adults with weak ankle muscles.
Plain-language title generated from the registry record
Registry title: Evaluation of the NEUROSWING Orthosis on Walking Speed in a Population With Dorsal and/or Plantar Flexor Deficits, With a View to a Reimbursement Application
Key facts
- Where
- Hérouville-Saint-Clair and La Membrolle-sur-Choisille, FranceSee the 2 sites
Where in France
- IMPR du Bois de LébiseyHérouville-Saint-Clair, FranceTaking people
- CMPR Bel-AirLa Membrolle-sur-Choisille, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ÖSSUR France
- Trial code
- NCT07108088
- Record updated
- 14 October 2026
- Original description
The aim of this randomized, cross-over, multi-center, intention-to-treat, open-label study study is to determine the benefits of the NEUROSWING device on gait speed in patients with dorsal and/or plantar flexor deficits, compared with the use of a carbon orthosis. Each patient will benefit in random order from a 14-day investigation period with the NEUROSWING device and a 14-day control period with a carbon orthosis. These two 2-week periods will be separated by one week, during which no orthosis will be worn and no evaluation will be carried out. Patients will be randomized to determine which phase they will start with. The primary endpoint is walking speed, which will be measured by comparing the results of the 10-meter walk test. For the secondary endpoints, patients will be assessed using the Functional Gait Assessment (FGA), the 6-minute test and an analysis system that will analyze other gait parameters (duration of the different phases of the gait cycle, cadence and step length). In order to carry out the assessments, each patient included will have 12 visits spread over 5 weeks.Read full original descriptionShow less
Evaluation of the NEUROSWING Orthosis on Walking Speed in a Population With Dorsal and/or Plantar Flexor Deficits, With a View to a Reimbursement Application. Clinical Investigation: NS-BOOSST
The aim of this randomized, cross-over, multi-center, intention-to-treat, open-label study study is to determine the benefits of the NEUROSWING device on gait speed in patients with dorsal and/or plantar flexor deficits, compared with the use of a carbon orthosis. Each patient will benefit in random order from a 14-day investigation period with the NEUROSWING device and a 14-day control period with a carbon orthosis. These two 2-week periods will be separated by one week, during which no orthosis will be worn and no evaluation will be carried out. Patients will be randomized to determine which phase they will start with. The primary endpoint is walking speed, which will be measured by comparing the results of the 10-meter walk test. For the secondary endpoints, patients will be assessed using the Functional Gait Assessment (FGA), the 6-minute test and an analysis system that will analyze other gait parameters (duration of the different phases of the gait cycle, cadence and step length). In order to carry out the assessments, each patient included will have 12 visits spread over 5 weeks.
Inclusion: 18 years of age and older; Deficit of the dorsal and/or plantar flexors with at least one of the following components specific to the indication of an AFO:; steppage; foot drop,; spasticity,; failure to transfer weight-bearing,; instability of weight-bearing phase; compensatory hyperextension of the knee; Muscular deficiency of the dorsal and/or plantar flexors principal or accessory; Ambulation possible with or without technical aids; First time using an orthosis used in the study; Being followed in one of the investigating centers whose management and rehabilitation in line with the study's visit schedule; Having freely consented to participate; Affiliated with a social security scheme.
Exclusion: Cognitive disorders, at the investigator's discretion, impacting the reliability of the clinical tests under study; Medically unstable (e.g. severe cardiovascular disorders) as judged by the investigating physician; Behavioral disorders (opposition, agitation, dementia) which, according to the investigator's judgment, would have an impact on walking; Person under psychiatric care or admitted to a health or social establishment for purposes other than research; Pathology in progressive phase at the time of inclusion that could significantly impact walking (e.g. MS, ALS, etc.) during the entire study period; Already fitted with a carbon or NEUROSWING orthosis; Height over 214cm; Weight over 193kg; Pregnant, parturient or breast-feeding women; Person deprived of liberty by a court order (including guardianship, curatorship and safeguard of justice) or administrative order; Person in an emergency situation unable to give consent beforehand.